FLGT - 3 Things About Fulgent Genetics That Smart Investors Know
During the COVID-19 pandemic, Fulgent Genetics (NASDAQ: FLGT) was in the right place at the right time . Fulgent became a key provider of COVID-19 testing in 2020 and saw its revenue explode by almost 1,300% over the prior year. Few companies benefited more during the pandemic -- and few have a bigger cloud of uncertainty hanging over them as investors worry about what comes next.
The good news is that Fulgent isn't a one-trick pony. The company is going through a metamorphosis, strengthened by a reinforced balance sheet and a growing core business in an attractive genetic testing market. Investors should prepare to shift their perspective.
Image source: Getty Images.
For further details see:
3 Things About Fulgent Genetics That Smart Investors Know